報價延遲最少15分鐘:2026/11/04 15:48 EST
盤後時段
|
||||
|
-- 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.615
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.16/0.19
|
|
企業價值
2.38B
|
| 資產負債 |
|
每股賬面淨值
5.28
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
22.50M
|
|
每股收益
0.12
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases. |
